Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
Clinical trial NCT02272998 · COMPLETED
Trial details
- NCT number
- NCT02272998
- Sponsor
- Sameek Roychowdhury
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-02-24
- Primary completion
- 2022-11-17
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.